Appealing Denials for Experimental or Investigational Treatments

When a health insurer classifies a treatment as experimental or investigational, the resulting denial can block access to therapies that a treating physician has specifically recommended. These denials represent one of the most contested categories in health insurance disputes, intersecting clinical evidence standards, plan contract language, and federal and state regulatory frameworks. This page covers the definition of "experimental or investigational" as used by insurers, the mechanics of the appeal process, common clinical scenarios that generate denials, and the evidentiary and procedural boundaries that determine outcomes.

Definition and Scope

Health insurers apply the label "experimental or investigational" (E&I) to treatments that have not achieved a level of clinical acceptance they regard as standard. The criteria vary by plan but typically track one or more of four conditions: the treatment lacks approval by the U.S. Food and Drug Administration (FDA) for the specific indication in question; the treatment is the subject of ongoing clinical trials under an FDA Investigational New Drug (IND) or Investigational Device Exemption (IDE) application; research-based medical literature does not yet support the treatment's safety or efficacy for that indication; or major professional bodies — such as the American Medical Association or specialty-specific organizations — have not adopted the treatment into clinical guidelines.

The Affordable Care Act (ACA), codified at 42 U.S.C. § 18001 et seq., does not eliminate E&I exclusions, but it does require non-grandfathered plans to provide external review rights for denials based on E&I determinations. The National Association of Insurance Commissioners (NAIC) model acts — including the Uniform Health Carrier External Review Model Act — establish minimum external review standards that 46 states and the District of Columbia have adopted in some form. Plans governed by ERISA (the Employee Retirement Income Security Act, 29 U.S.C. § 1001 et seq.) follow the U.S. Department of Labor's claims and appeals regulations at 29 C.F.R. § 2560.503-1.

For a broader orientation to how denial categories intersect, the types of insurance appeals framework provides useful structural context.

How It Works

The appeal pathway for an E&I denial follows a structured sequence. Under federal minimum standards, group health plans must provide at least one internal appeal and, if the internal appeal is unsuccessful, access to external review by an accredited Independent Review Organization (IRO).

1. Obtain the denial notice. Insurers are required to provide a written denial explaining the specific E&I criteria applied and identifying the clinical evidence or plan language used. This document anchors the entire appeal.
2. Request the plan's clinical criteria. Under ERISA § 503 and ACA implementing regulations, plans must disclose the clinical guidelines, internal policies, and InterQual or MCG (formerly Milliman Care Guidelines) criteria used in the determination, upon request.
3. File the internal appeal. The ACA requires internal appeals to be decided within 60 days for post-service claims and 30 days for pre-service claims (45 C.F.R. § 147.136). The appeal submission should include a physician letter of medical necessity, research-based literature supporting the treatment, and any applicable clinical trial enrollment documentation.
4. Request expedited review if applicable. For urgent situations, expedited internal appeals must be decided within 72 hours. The urgent and expedited insurance appeals process is a separate track with distinct procedural rules.
5. Proceed to external review. If the internal appeal fails, external review by an IRO provides an independent clinical judgment. IRO decisions are binding on the insurer in most states. The external review process and the role of independent review organizations are governed by either state law or, for ERISA plans in states without conforming statutes, federal standards administered by the Department of Labor.
6. Escalate to regulatory or legal channels. Unresolved disputes may be directed to a state insurance department or pursued through litigation.

Common Scenarios

E&I denials cluster around identifiable clinical categories:

• Off-label drug use. A drug is FDA-approved but prescribed for an indication not listed on its label. Oncology is the most concentrated area — the National Comprehensive Cancer Network (NCCN) compendium is frequently cited in appeals to establish off-label use as accepted practice, and at least 40 states have enacted statutes requiring coverage of off-label cancer treatments supported by NCCN or similar compendia.
• Gene therapies and CAR-T cell treatments. Despite FDA approval for specific blood cancers, insurers sometimes apply E&I language to patients who fall outside the exact approved indication or who are being treated at centers outside the plan's network coverage criteria.
• Proton beam therapy. Coverage determinations vary sharply by indication. Pediatric brain tumors have broader insurer acceptance than adult prostate cancer, where clinical evidence remains contested.
• Clinical trial participation. The ACA requires non-grandfathered plans to cover routine costs of care associated with approved clinical trials (42 U.S.C. § 300gg-8), but the definition of "routine costs" is a recurring dispute point.
• Emerging mental health treatments. Transcranial magnetic stimulation (TMS) and ketamine infusion therapy have generated growing E&I denial volumes as their use has expanded beyond original approved indications. Appeals in this category intersect with the Mental Health Parity and Addiction Equity Act (MHPAEA), which prohibits more restrictive E&I criteria for mental health benefits than for analogous medical/surgical benefits (29 U.S.C. § 1185a).

Decision Boundaries

The outcome of an E&I appeal turns on a small set of determinative factors. Understanding where the decision lines fall is essential for structuring an effective submission.

FDA approval status vs. clinical acceptance. These are not the same standard, and conflating them is a common insurer error. A treatment can be FDA-approved for one indication and qualify as accepted practice for a second indication based on compendia or research-based literature. Appeals that document this distinction — citing the specific compendium entry or journal citation — have a materially different evidentiary profile than those that rely solely on physician opinion letters.

Plan language specificity. Some plans define E&I by reference to objective external criteria (NCCN, Hayes Medical Technology Directory, Blue Cross Blue Shield Association Technology Evaluation Center criteria). Others use internal clinical policies. Where the plan references external criteria, the appeal can directly contest whether those criteria are met. Where it uses internal criteria, the external review mechanism becomes the primary corrective tool, because IROs apply independent clinical standards rather than the plan's proprietary definitions.

MHPAEA parity analysis. For mental health or substance use disorder treatments, a denial based on E&I criteria must survive a parity comparison: the insurer must be able to demonstrate that it applies the same E&I standards to analogous medical or surgical conditions. The Department of Labor's 2023 MHPAEA Report to Congress found widespread plan non-compliance with this requirement, providing appellants with regulatory leverage.

IRO composition and accreditation. IROs must be accredited by URAC or a similar accrediting body and must use reviewers who are board-certified in the relevant specialty and have no financial relationship with the insurer. The specific specialty match between the IRO reviewer and the denied treatment is a legitimate basis for challenging an IRO assignment if the match is inadequate.

For those preparing a submission, the evidence required for insurance appeals resource outlines documentation standards in detail, and writing an insurance appeal letter addresses how to structure the clinical and regulatory argument. The intersection of E&I denials with employer-sponsored plan rules is covered in depth at ERISA appeals for employer-sponsored plans.

References

• U.S. Food and Drug Administration (FDA) — Drug Approvals and Databases
• U.S. Department of Health and Human Services — Affordable Care Act Overview
• U.S. Department of Labor — ERISA Claims Procedure Regulation, 29 C.F.R. § 2560.503-1
• U.S. Department of Labor — 2023 MHPAEA Report to Congress
• [Electronic Code of Federal Regulations — 45 C